Plus Therapeutics Inc (PSTV)

$ 2.31
-0.09 (-3.75%)
-
Symbol PSTV
Price $ 2.31
Beta 0.349
Volume Avg. 1.58M
Market Cap 0.05B
Shares () -
52 Week Range 1.51-5.42
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -364.77% Strong Sell
ROA -68.08% Strong Sell
Operating Margin -
Debt / Equity 299.37% Strong Buy
P/E -
P/B 3.36 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

PSTV Stock: From $2.60 To $2.84 (9.23% Increase) Pre-Market Explanation

PSTV Stock: From $2.60 To $2.84 (9.23% Increase) Pre-Market Explanation

The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) went from $2.60 to $2.84 (up 9.23%) pre-market. This is why it happened. ...

Pulse2
Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements

Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreement...

– Agreements are a major step for ongoing clinical trials and future commercial drug supply – Agreements are a major step for ongoing clinical trials and future commercial drug supply ...

GlobeNewsWire
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript ...

Seeking Alpha
Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

Management to host conference call today at 5:00 pm ET Management to host conference call today at 5:00 pm ET ...

GlobeNewsWire
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021

Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April...

AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announc... ...

GlobeNewsWire
PSTV Stock Price Increases Over 40% Pre-Market: Why It Happened

PSTV Stock Price Increases Over 40% Pre-Market: Why It Happened

The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased by over 40% pre-market. This is why it happened. ...

Pulse2
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization

Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Con...

Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets ...

GlobeNewsWire
Plus Therapeutics to Participate in Upcoming Virtual Conferences

Plus Therapeutics to Participate in Upcoming Virtual Conferences

AUSTIN, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc ... ...

GlobeNewsWire
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript ...

Seeking Alpha
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlight...

– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 – ...

GlobeNewsWire

About


Dr. Marc Hedrick
Healthcare
Biotechnology
Nasdaq Global Select

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. The company is headquartered in Austin, Texas and currently employs 37 full-time employees. The firm is focused on developing treatments for patients battling cancer. The firm provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The firm is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The firm is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma.